Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
Yuming Zou (鄒宇鳴), aged 44, is a seasoned financial executive with over 20 years of experience across global capital markets, investment banking, and corporate finance. He currently serves in dual leadership roles as Chief Financial Officer and Director of Muzero Acquisition Corp. (NASDAQ: MUZE), a Cayman Islands-incorporated, New York-based blank check company targeting technology-enabled businesses, and as Executive Director and Chief Financial Officer of Fangzhou Inc. (方舟云康控股有限公司, HKEX: 6086), a leading Chinese internet healthcare and chronic disease management platform. At Muzero, Zou is part of a management team led by Chairman Sheldon Trainor-DeGirolamo (founder and Managing Director of PacBridge Capital Partners) and CEO and Director Von Lam (founder and Managing Partner of Falcon Partners). The SPAC raised $175 million in its January 2026 IPO, pricing 17.5 million units at $10 each, with each unit consisting of one share of common stock and one-half of one warrant exercisable at $11.50 per share, and ultimately closed its IPO at $201.25 million. Zou also participated as a sponsor, acquiring 335,938 shares at $10.00 per share (totaling $3,359,380) through Muzero Acquisition Sponsors LLC. The company must complete its initial business combination by February 2, 2028, the end of its 24-month combination period.
Zou's career began at J.P. Morgan, where he spent 15 years and rose to the position of Executive Director in the Asia Pacific Investment Bank. During his tenure, he was responsible for investment banking, financial market trading, and other major business lines, holding important positions across J.P. Morgan's offices in New York, Beijing, Shanghai, and Hong Kong. His specialties span mergers and acquisitions, corporate finance, structured credit, hedge fund structured products, and illiquid asset financing, reflecting deep expertise in both traditional and alternative capital markets. In 2018, Zou joined Fangzhou Jianke Group (the predecessor to Fangzhou Inc.) as Senior Vice President of Strategic Development, where he laid a solid foundation for the company's growth across strategic development, finance, investment and financing, and investor relations. In June 2021, he was appointed Chief Financial Officer, assuming responsibility for the overall planning and management of the group's development, finance, and investment and financing activities. He has served as a Director of Fangzhou since August 9, 2021, and also holds the role of Joint Company Secretary at the company.
At Fangzhou, Zou serves on the board alongside Executive Director and CEO Wang Haijiao, Executive Director and Chief Strategy Officer Zhou Feng, Non-Executive Director and Chairman David McKee Hand, and independent non-executive directors Wang Haizhong, Kang Wei, and Zhu Xiaolu. The company is focused on building an H2H (hospital-to-home) intelligent healthcare ecosystem through its series of internet hospitals, cloud-based chronic disease management platforms, and well-known pharmaceutical e-commerce operations. Zou's extensive cross-border capital markets experience and his track record across multiple geographies and asset classes position him as a key figure in both Fangzhou's public market governance and Muzero's search for a technology-enabled business combination target. Based in Hong Kong, Zou brings to his SPAC role a combination of deep Asian market knowledge and global financial expertise cultivated over more than two decades in investment banking and corporate leadership.
This record is keyed to SEC CIK 0002103810 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 3 institutional-holder rows on these vehicles, under 3 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.